- Company-wide research offers novel pathways for enhancing kidney patient care using data-driven insights and real-world evidence
Ģý, the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of over 60 company-affiliated research abstracts at the American Society of NephrologyĢýs (ASN) taking place November 2-5 in Philadelphia.
ĢýThe scientific and medical breadth of research presented this year highlights the power of ĢýĢýs global scope and scale in creating data-driven insights that have the potential to improve patient care and outcomes,Ģý said Dr. Frank Maddux, Global Chief Medical Officer and Member of the Management Board for Ģý. ĢýOur presentations cover key topics including advances in machine learning and artificial intelligence in kidney care, using big data and real-world evidence to drive insights, advancing home dialysis, and research around hemodiafiltration (HDF) and hemodialysis (HD) therapies. We look forward to sharing our insights at this yearĢýs conference.Ģý
Scientific and medical experts from across Ģý will present research related to many important topics in kidney disease care. A link to all Ģý-affiliated presentations can be found on our companyĢýs website: . Highlights of this yearĢýs presentations for the medical congress include:
Artificial Intelligence and Data Science:
- (November 2, 10:00 AM Ģý 12:00 PM): Education on a machine learning predictive model which identifies in-center hemodialysis patients who would be good candidates for home therapy.
- (November 3, 10:00 AM Ģý 12:00 PM): Presenting a risk score which accurately and reproducibly predicts AVF failure within 3 months that may offer a cheaper and automated alternative to Qa measurement.
Data-Driven Global Insights:
- (November 2, 10:00 AM Ģý 12;00 PM): Capturing data from over 40 countries, Apollo DB is an anonymized dialysis database that combines and harmonizes data from a global provider for research and quality improvement activities.
- (November 2, 10:00 AM Ģý 12:00 PM): Research captured from 20 years of longitudinal patient data contributed to the new MONDO dataset, the most robust global dialysis dataset in the world.
- (November 4, 10:00 AM Ģý 12:00 PM): Experts present a study designed to evaluate if CrCl predicts longitudinal PO4 irrespective of achieved Kt/V.
Hemodiafiltration (HDF) and Hemodialysis (HD) Research:
- (November 2, 10:00 AM Ģý 12:00 PM): Presenting a comparison of hospital admissions among Fresenius Kidney Care (FKC) clinics with high utilization of RBV and propensity score matched (PSM) clinics not using RBV.
- Real-World Effectiveness of Hemodialysis Modalities (November 2, 10:00 AM Ģý 12:00 PM): A late-breaking abstract that provides real world evidence demonstrating comparison of patients treated with hemodialysis vs hemodiafiltration.
- (November 3, 10:00 AM Ģý 12:00 PM): eMPORA III was a multi-center crossover trial with 4-week randomized treatment periods comparing dialyzer performance (FX CorAL 600 vs two comparable high-flux dialyzers) in post-dilution online hemodiafiltration (HDF).
- (November 3, 10:00 AM Ģý 12:00 PM): The CONVINCE Scientific Committee and CONVINCE Investigators present the survey developed based on the KDQOL symptoms scale with an adapted recall period of 7 days for interdialytic symptoms and extended inter- and intradialytic (IDS) items based on literature review and patient interviews.
Ģý is the world's leading provider of products and services for individuals with renal diseases of which around 3.9 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,050 dialysis clinics, Ģý provides dialysis treatments for approximately 344,000 patients around the globe. Ģý is also the leading provider of dialysis products such as dialysis machines or dialyzers. Ģý is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Ģý AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Ģý AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.